We are live on ! Find out more
PCRX icon

Pacira BioSciences

214 hedge funds and large institutions have $3.29B invested in Pacira BioSciences in 2015 Q4 according to their latest regulatory filings, with 62 funds opening new positions, 70 increasing their positions, 66 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

170% more first-time investments, than exits

New positions opened: 62 | Existing positions closed: 23

120% more funds holding in top 10

Funds holding in top 10: 511 (+6)

87% more capital invested

Capital invested by funds: $1.76B → $3.29B (+$1.53B)

21% more funds holding

Funds holding: 177214 (+37)

6% more repeat investments, than reductions

Existing positions increased: 70 | Existing positions reduced: 66

39% less call options, than puts

Call options by funds: $29M | Put options by funds: $47.5M

Holders
214
Holders Change
+37
Holders Change %
+20.9%
% of All Funds
5.61%
Holding in Top 10
11
Holding in Top 10 Change
+6
Holding in Top 10 Change %
+120%
% of All Funds
0.29%
New
62
Increased
70
Reduced
66
Closed
23
Calls
$29M
Puts
$47.5M
Net Calls
-$18.5M
Net Calls Change
-$18.2M
Name Holding Trade Value Shares
Change
Change in
Stake
CPS
76
Counsel Portfolio Services
Ontario, Canada
$4.15M +$656K +11,588 +27%
NIP
77
Nicholas Investment Partners
California
$3.9M +$852K +15,054 +42%
CS
78
Credit Suisse
Switzerland
$3.9M +$640K +11,305 +29%
IHM
79
Iguana Healthcare Management
New York
$3.84M +$2.83M +50,000 New
AA
80
ALPS Advisors
Colorado
$3.72M -$506K -8,938 -16%
GH
81
GAM Holding
Switzerland
$3.66M
DCM
82
Driehaus Capital Management
Illinois
$3.65M +$1.97M +34,755 +271%
Swiss National Bank
83
Swiss National Bank
Switzerland
$3.62M
AIC
84
AWM Investment Company
New York
$3.6M -$3.86M -68,200 -59%
GC
85
Guggenheim Capital
Illinois
$3.29M +$1.9M +33,606 +365%
RhumbLine Advisers
86
RhumbLine Advisers
Massachusetts
$3.26M +$179K +3,160 +8%
EI
87
EAM Investors
California
$3M +$2.21M +39,026 New
ProShare Advisors
88
ProShare Advisors
Maryland
$2.78M +$197K +3,477 +11%
RPAM
89
Rhenman & Partners Asset Management
Sweden
$2.69M +$1.98M +35,000 New
NFA
90
Nationwide Fund Advisors
Ohio
$2.62M -$1.53M -27,044 -44%
ARTA
91
A.R.T. Advisors
New York
$2.56M -$607K -10,727 -24%
Barclays
92
Barclays
United Kingdom
$2.55M +$1.23M +21,657 +181%
SFP
93
Santa Fe Partners
New Mexico
$2.43M -$507K -8,956 -22%
GTC
94
Ghost Tree Capital
New York
$2.3M -$2.83M -50,000 -63%
KBC Group
95
KBC Group
Belgium
$2.15M +$1.53M +27,018 +2,686%
State Board of Administration of Florida Retirement System
96
State Board of Administration of Florida Retirement System
Florida
$2.05M
Baillie Gifford & Co
97
Baillie Gifford & Co
United Kingdom
$2.01M
MLICM
98
Metropolitan Life Insurance Company (MetLife)
New York
$1.97M -$10.4K -184 -0.7%
MOACM
99
Mutual of America Capital Management
New York
$1.86M +$8.04K +142 +0.6%
LCG
100
Lisanti Capital Growth
New York
$1.85M +$1.36M +24,035 New

PCRX Hedge Fund Activity: Q4 2015 in Review

214 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Pacira BioSciences (PCRX) for Q4 2015, worth a combined $3.29B — up 87% from $1.76B a quarter earlier.

Buyers outnumbered sellers: 62 funds opened new PCRX positions and 23 closed out — a net gain of 39 holders — while 70 added to existing stakes and 66 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $53.1M. The largest seller was Ameriprise, cutting an estimated $52.9M.

  • 214 institutional investors held Pacira BioSciences (PCRX) as of Q4 2015, up from 177 in Q3 2015.
  • Funds reported $3.29B of Pacira BioSciences stock for Q4 2015, up 87% quarter-over-quarter.
  • 62 funds opened new Pacira BioSciences positions in Q4 2015 and 23 closed out, a net change of +39 holders.
  • The largest Pacira BioSciences buyer in Q4 2015 was Fidelity Investments, an estimated $53.1M added.
  • The largest Pacira BioSciences seller in Q4 2015 was Ameriprise, an estimated $52.9M sold.

Based on aggregated 13F filings for Q4 2015.